Systematic overview of cost-utility assessments in oncology.
about
Interferon-alpha for maintenance of follicular lymphomaInterferon-alpha for follicular lymphomaWhen is cancer care cost-effective? A systematic overview of cost-utility analyses in oncologyTwenty years of cost-effectiveness analysis in medical imaging: are we improving?Navigational bronchoscopy with biopsy versus computed tomography-guided biopsy for the diagnosis of a solitary pulmonary nodule: a cost-consequences analysisHow long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments.Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review.Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?The value of health care--a matter of discussion in Germany.Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutationsSafety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.A simulation model approach to analysis of the business case for eliminating health care disparities.Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancerCost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriersCost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1.Ethical issues in autologous stem cell transplantation (ASCT) in advanced breast cancer: a systematic literature review.A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.Cost-effectiveness of computed tomography screening for lung cancer in the United StatesIs prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, CanadaQuality of life implications of bisphosphonate-associated osteonecrosis of the jaw.Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancerOnline tool to guide decisions for BRCA1/2 mutation carriers.Can differences in breast cancer utilities explain disparities in breast cancer care?Estimating the benefit and cost of radiotherapy for lung cancer.Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy.Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds.Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer.Evaluation of patients with clinically detected recurrence of rectal carcinoma: Current practice patterns of colorectal surgeonsCost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy ModelImpact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancerHealth state utilities for metastatic breast cancer.Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain.Cost-effectiveness analysis of whole-mount pathology processing for patients with early breast cancer undergoing breast conservationQuantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer.Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer.Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.Targeted therapies for hepatocellular carcinoma.
P2860
Q24240781-C9DCA99F-805A-426E-96F5-99FF383E098BQ24247519-0773AE8A-8C1E-4694-875F-56E80FD175DCQ24645229-37AF0AC8-2386-48E8-BF1E-AD1D6F02841AQ24650469-CAA57D37-7395-44D1-AEFE-F2E6A9E41735Q27008251-229F422B-AA48-42EE-B5A8-38A9776BE096Q30226892-94D8D447-7716-4218-8BEA-277121F81E0AQ30251912-F244CCD2-6DE8-458F-BD97-2715C328DAE6Q30496856-242F223B-BD1C-4CF7-9211-5572C911747FQ30828900-5EB89708-0E9F-4BE1-BA1F-0564E2647DA8Q33289667-A27D5B5C-D76D-453A-A268-1E8D8B2BAC6EQ33392652-773A6474-CD3E-448B-81EE-DEA02518B8AEQ33515843-C395B0D6-8299-4940-8401-E194FC90AE02Q33850319-5E34F807-57AE-43EF-98EF-77FBFE7A181CQ34022200-242A655D-6911-41D5-826A-358B6F935CE8Q34431985-33E8955C-DA2D-4D49-9D8B-DE8EE62000FDQ34803360-2AEE7F76-E463-45F0-80DC-916884E81251Q35002445-A457423B-749C-4D80-80FD-502CBF25C71EQ35011451-1AB8A0BE-6C1F-4C0F-98BA-C103180FA48DQ35034768-16B1E05A-A91D-4DE6-8E7A-C4AC1375641FQ35451969-1E78AE19-7043-4272-8BBC-550E97A90CDCQ35541638-AC66B9A7-6B66-45E8-9BE5-70859F7A0A7BQ35584343-ED9A231D-8F22-4E5F-B728-49360320CCD4Q35776211-8A12726E-4CB6-4175-8EEF-91DFD3E3E0B5Q35808372-9EE64B9C-50CB-47FA-956E-094E19B6334EQ35901636-848C546C-6C50-404B-AD57-D29DFBAFED21Q35989253-89350301-0B6C-4D17-8380-CBEB43FA8DF1Q36053946-DFEFD2C0-CAD2-4D3D-B6B9-CC53F01F4F06Q36117463-A11DC5CC-0BD7-4013-93B8-1A77137E6E2AQ36177951-AFC43D63-39D7-4CE0-9F31-354736184701Q36216560-88EAA537-93D5-4265-8EBB-788467CD24FCQ36332037-AE81C4BF-69E0-4503-A23D-14E3B1DD2EC9Q36394607-0AF669F9-1260-4A3B-8A75-71737C6A0768Q36591214-4A174793-16A6-4F49-9CA6-181A00F8E04EQ36648401-DB12785C-BB24-4409-BA6F-CE39412A17E8Q36658832-2A51E95F-5589-41D5-AE08-1FA920E98CAFQ36695170-04D58074-3A0D-4496-9125-0EA9E0109981Q36699064-EEB461EB-DCAD-4302-A43F-A4C216F48A88Q36738628-E05F0A51-C33B-47BC-BCBF-258E8A8A5F51Q36859184-DA0A56E8-8BCD-48C0-AC5B-441EE33D6620Q36928888-FFC5EDF2-6978-4B21-A873-54ADF9E4E9CE
P2860
Systematic overview of cost-utility assessments in oncology.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Systematic overview of cost-utility assessments in oncology.
@ast
Systematic overview of cost-utility assessments in oncology.
@en
Systematic overview of cost-utility assessments in oncology.
@nl
type
label
Systematic overview of cost-utility assessments in oncology.
@ast
Systematic overview of cost-utility assessments in oncology.
@en
Systematic overview of cost-utility assessments in oncology.
@nl
prefLabel
Systematic overview of cost-utility assessments in oncology.
@ast
Systematic overview of cost-utility assessments in oncology.
@en
Systematic overview of cost-utility assessments in oncology.
@nl
P2093
P1476
Systematic overview of cost-utility assessments in oncology.
@en
P2093
E A Sandberg
P J Neumann
R H Chapman
P304
P356
10.1200/JCO.2000.18.18.3302
P407
P577
2000-09-01T00:00:00Z